Users Stopping Anti-Obesity Injections Gain Back Weight Far More Rapidly Than Dieters

Fresh analysis suggests that people who stop using new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop conventional lifestyle plans.

Findings released in a major medical journal shows that while obese people frequently drop substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month after stopping.

"Individuals using these drugs must be informed of the potential of quick rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.

This pace of regain suggests a reversion to original weight in about 18 months.

Analyzing Therapies

The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.

Scientists note that individuals who lose weight through lifestyle changes alone typically see a more gradual weight regain—around 0.1 kg a month—post-intervention.

Explaining the Quick Regain

Experts believe the way of the drugs explains the heightened regain.

GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.

"Artificially providing the hormone concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this hormone supplement means hunger is uncontrolled, making overeating much more probable."

A Lifelong Condition?

Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.

Professionals argue that, due to the high risk of weight regain, the treatment should be considered life-long.

This view is supported by pharmaceutical companies, who say that the results "highlight the long-term character of obesity," comparing it to managing conditions like hypertension.

Patient Testimonies

Users who have come off the medication explain a powerful resurgence of hunger.

"It felt as if a switch activating and you're instantly extremely hungry," recalled one woman.

The struggle is exacerbated if users have not adopted sustainable lifestyle or habit changes during treatment.

Growing Use

Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with desire being substantial.

• Use is more common among females compared to males.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion access the drugs through private healthcare rather than public health services.

In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and lasting health benefits relies on combined behavioural support.